Nykode Therapeutics CEO after another million-dollar deal: We have no competitors
Nykode Therapeutics – formerly Vaccibody – is not up for sale despite the fact that some of the world's biggest biotech businesses are fawning over its technology. CEO Michael Engsig says that they're open to partnerships, even though the company is economically sorted for the future.
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
Some of the biggest biotech players in the world are swarming around the Norwegian company Nykode Therapeutics, which was named Vaccibody until yesterday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New Sanofi study is yet another win for blockbuster drug
For subscribers
Anthony Mancini will help Genmab take its next steps
For subscribers
Stockholm wants to become leading life science region
For subscribers
